Drug General Information |
Drug ID |
D03SHR
|
Former ID |
DNC005411
|
Drug Name |
IBUPROPHEN
|
Drug Type |
Small molecular drug
|
Indication |
Discovery agent
|
Investigative |
[1]
|
Structure |
|
Download
2D MOL
3D MOL
|
Formula |
C13H18O2
|
Canonical SMILES |
CC(C)CC1=CC=C(C=C1)C(C)C(=O)O
|
InChI |
1S/C13H18O2/c1-9(2)8-11-4-6-12(7-5-11)10(3)13(14)15/h4-7,9-10H,8H2,1-3H3,(H,14,15)
|
InChIKey |
HEFNNWSXXWATRW-UHFFFAOYSA-N
|
CAS Number |
CAS 15687-27-1
|
PubChem Compound ID |
|
Target and Pathway |
Target(s) |
High affinity interleukin-8 receptor A |
Target Info |
Inhibitor |
[1]
|
High affinity interleukin-8 receptor B |
Target Info |
Inhibitor |
[1]
|
Interleukin-8 |
Target Info |
Inhibitor |
[2]
|
KEGG Pathway
|
Cytokine-cytokine receptor interaction
|
Chemokine signaling pathway
|
Endocytosis
|
Epithelial cell signaling in Helicobacter pylori infectionhsa04060:Cytokine-cytokine receptor interaction
|
NF-kappa B signaling pathway
|
Toll-like receptor signaling pathway
|
NOD-like receptor signaling pathway
|
RIG-I-like receptor signaling pathway
|
Non-alcoholic fatty liver disease (NAFLD)
|
Epithelial cell signaling in Helicobacter pylori infection
|
Shigellosis
|
Salmonella infection
|
Pertussis
|
Legionellosis
|
Chagas disease (American trypanosomiasis)
|
Malaria
|
Amoebiasis
|
Hepatitis C
|
Hepatitis B
|
Influenza A
|
Pathways in cancer
|
Transcriptional misregulation in cancer
|
Bladder cancer
|
Rheumatoid arthritis
|
NetPath Pathway
|
IL2 Signaling PathwayNetPath_9:TNFalpha Signaling PathwayNetPath_19:IL-7 Signaling Pathway
|
IL5 Signaling Pathway
|
IL1 Signaling Pathway
|
TSH Signaling Pathway
|
IL2 Signaling Pathway
|
IL3 Signaling Pathway
|
IL4 Signaling Pathway
|
TNFalpha Signaling Pathway
|
TSLP Signaling Pathway
|
TCR Signaling Pathway
|
PANTHER Pathway
|
Inflammation mediated by chemokine and cytokine signaling pathway
|
Interleukin signaling pathwayP00031:Inflammation mediated by chemokine and cytokine signaling pathway
|
Interleukin signaling pathway
|
CCKR signaling map ST
|
Pathway Interaction Database
|
IL8- and CXCR1-mediated signaling eventsil8cxcr2_pathway:IL8- and CXCR2-mediated signaling eventslysophospholipid_pathway:LPA receptor mediated events
|
Calcineurin-regulated NFAT-dependent transcription in lymphocytes
|
Validated transcriptional targets of AP1 family members Fra1 and Fra2
|
Glucocorticoid receptor regulatory network
|
ATF-2 transcription factor network
|
IL8-mediated signaling events
|
AP-1 transcription factor network
|
IL8- and CXCR2-mediated signaling events
|
Regulation of nuclear beta catenin signaling and target gene transcription
|
Syndecan-2-mediated signaling events
|
Syndecan-3-mediated signaling events
|
IL8- and CXCR1-mediated signaling events
|
Reactome
|
Chemokine receptors bind chemokines
|
G alpha (i) signalling eventsR-HSA-380108:Chemokine receptors bind chemokines
|
G alpha (i) signalling eventsR-HSA-2559582:Senescence-Associated Secretory Phenotype (SASP)
|
Peptide ligand-binding receptors
|
ATF4 activates genes
|
G alpha (i) signalling events
|
WikiPathways
|
GPCRs, Class A Rhodopsin-like
|
Differentiation Pathway
|
Peptide GPCRs
|
GPCR ligand binding
|
GPCR downstream signaling
|
GPCRs, OtherWP455:GPCRs, Class A Rhodopsin-like
|
GPCRs, OtherWP75:Toll-like receptor signaling pathway
|
SIDS Susceptibility Pathways
|
Senescence and Autophagy in Cancer
|
IL-3 Signaling Pathway
|
Bladder Cancer
|
Activation of Genes by ATF4
|
EBV LMP1 signaling
|
Spinal Cord Injury
|
Corticotropin-releasing hormone
|
Allograft Rejection
|
TSLP Signaling Pathway
|
Regulation of toll-like receptor signaling pathway
|
References |
REF 1 | J Med Chem. 2005 Jun 30;48(13):4312-31.2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. |
---|
REF 2 | Bioorg Med Chem Lett. 2009 Aug 1;19(15):4026-30. Epub 2009 Jun 13.Structure-Activity Relationship of novel phenylacetic CXCR1 inhibitors. |